MX338980B - Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9. - Google Patents

Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9.

Info

Publication number
MX338980B
MX338980B MX2012014904A MX2012014904A MX338980B MX 338980 B MX338980 B MX 338980B MX 2012014904 A MX2012014904 A MX 2012014904A MX 2012014904 A MX2012014904 A MX 2012014904A MX 338980 B MX338980 B MX 338980B
Authority
MX
Mexico
Prior art keywords
tlr7
methods
treatment
tlr9
inhibitors
Prior art date
Application number
MX2012014904A
Other languages
English (en)
Other versions
MX2012014904A (es
Inventor
Franck Barrat
Robert L Coffman
Cristina Guiducci
Original Assignee
Dynavax Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp filed Critical Dynavax Tech Corp
Publication of MX2012014904A publication Critical patent/MX2012014904A/es
Publication of MX338980B publication Critical patent/MX338980B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a composiciones y métodos para regular una respuesta inmune, que comprenden inhibidores de TLR7 y TLR9, tales como polinucleótidos inmunoreguladores y/o compuestos inmunoreguladores. La solicitud también se refiere a composiciones y métodos para predecir y/o determinar la capacidad de respuesta de una enfermedad a un tratamiento que comprende inhibidores de TLR7 y/o TLR9.
MX2012014904A 2010-06-16 2011-06-16 Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9. MX338980B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35554710P 2010-06-16 2010-06-16
US41528910P 2010-11-18 2010-11-18
US42307610P 2010-12-14 2010-12-14
PCT/US2011/040788 WO2011159958A2 (en) 2010-06-16 2011-06-16 Methods of treatment using tlr7 and/or tlr9 inhibitors

Publications (2)

Publication Number Publication Date
MX2012014904A MX2012014904A (es) 2013-08-08
MX338980B true MX338980B (es) 2016-05-06

Family

ID=45348881

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014904A MX338980B (es) 2010-06-16 2011-06-16 Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9.

Country Status (11)

Country Link
US (2) US8940310B2 (es)
EP (1) EP2582398B1 (es)
KR (1) KR101810593B1 (es)
CN (1) CN103153346A (es)
AU (1) AU2011268211B2 (es)
BR (1) BR112012032240A2 (es)
CA (1) CA2802873C (es)
EA (1) EA201291357A1 (es)
MX (1) MX338980B (es)
SG (1) SG186380A1 (es)
WO (1) WO2011159958A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2703931C (en) * 2007-10-26 2016-08-16 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
US8940310B2 (en) 2010-06-16 2015-01-27 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
US9228184B2 (en) * 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
US9868955B2 (en) 2012-09-29 2018-01-16 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
WO2014110081A1 (en) * 2013-01-08 2014-07-17 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
JP6527516B2 (ja) 2013-12-03 2019-06-05 ノースウェスタン ユニバーシティ リポソーム粒子、前述のものを作製する方法及びその使用
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016134422A1 (en) * 2015-02-26 2016-09-01 Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research A method of treatment
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
CN114807152A (zh) 2016-06-08 2022-07-29 哈佛学院院长及董事 工程化病毒载体减少了炎症和免疫反应的诱导
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
CN119548615A (zh) * 2017-06-30 2025-03-04 皇家墨尔本理工大学 一种治疗方法
KR20200028997A (ko) 2017-07-13 2020-03-17 노오쓰웨스턴 유니버시티 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
ES2910974T3 (es) 2017-07-27 2022-05-17 Inst Nat Sante Rech Med Métodos para determinar si un paciente que padece rabdomiólisis logra una respuesta con un antagonista de TLR9
EP3707262A1 (en) 2017-11-08 2020-09-16 President and Fellows of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
MX2020010410A (es) 2018-04-09 2021-01-15 Checkmate Pharmaceuticals Empaquetado de oligonucleotidos en particulas similares a virus.
US20210215692A1 (en) * 2018-06-11 2021-07-15 University Of Washington Compositions and methods for treating inflammatory diseases
EP3856343A1 (en) 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
US11504425B2 (en) * 2019-02-26 2022-11-22 Wayne State University Amphiphilic oligodeoxynucleotide conjugates as adjuvant enhancers
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
IL298667A (en) * 2020-06-11 2023-01-01 Bristol Myers Squibb Co tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for the treatment of cutaneous lupus erythematosus
KR20230165907A (ko) * 2021-04-08 2023-12-05 허드슨 인스티튜트 오브 메디컬 리서치 올리고뉴클레오티드
WO2024100139A1 (en) * 2022-11-09 2024-05-16 Merck Patent Gmbh Use of ifn-i activity as a biomarker for tlr inhibitor treatment

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4849513A (en) 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5015733A (en) 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
US4910300A (en) 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US5093232A (en) 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US6312679B1 (en) 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
US5338532A (en) 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
PT88550A (pt) 1987-09-21 1989-07-31 Ml Tecnology Ventures Lp Processo para a preparacao de reagentes de ligacao nao nucleotidicos para sondas nucleotidicas
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US6096722A (en) 1990-08-14 2000-08-01 Isis Pharmaceuticals Inc. Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JPH09502092A (ja) 1993-09-02 1997-03-04 リボザイム・ファーマシューティカルズ・インコーポレイテッド 非ヌクレオチドを含有する酵素性核酸
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
EP0954531A1 (en) 1996-06-06 1999-11-10 Lajolla Pharmaceutical Company aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6489304B2 (en) 1997-05-01 2002-12-03 Hybridon, Inc. Hyperstructure-forming carriers
JP4101888B2 (ja) 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
US6080580A (en) 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
EP1176966B1 (en) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
CN1762990A (zh) 1999-06-08 2006-04-26 拉卓拉药物公司 包含氨基氧基的化合价平台分子
TR200200797T2 (tr) 1999-09-25 2002-10-21 University Of Iowa Research Foundation İmmünostimülatör nükleik asitler
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
WO2001068697A2 (en) 2000-03-17 2001-09-20 Gorczynski Reginald M Methods and compositions for immunoregulation
JP2003529774A (ja) 2000-03-31 2003-10-07 ジェネンテック・インコーポレーテッド 遺伝子発現を検出し定量するための構成物及び方法
US6498013B1 (en) 2000-07-28 2002-12-24 The Johns Hopkins University Serial analysis of transcript expression using MmeI and long tags
EP1414845A4 (en) 2001-03-21 2009-07-08 Human Genome Sciences SEPARATE HUMAN PROTEINS
WO2003085110A2 (en) 2002-04-05 2003-10-16 Santaris Pharma A/S Oligomeric compounds for the modulation hif-1alpha expression
SE0201701D0 (sv) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
AU2003243409A1 (en) 2002-06-05 2003-12-22 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
SG172476A1 (en) 2002-08-12 2011-07-28 Dynavax Tech Corp Immunomodulatory compositions comprising a cationic condensing agent, an immunostimulatory compound comprising 5'-cg-3', an a non ionic detergent
US7118865B2 (en) 2002-08-16 2006-10-10 Regents Of The University Of Minnesota Methods for diagnosing severe systemic lupus erythematosus
NZ540276A (en) 2002-11-21 2007-12-21 Bayhill Therapeutics Inc Methods and immune modulatory nucleic acid compositions for preventing and treating disease
ES2381309T3 (es) 2002-12-23 2012-05-25 Dynavax Technologies Corporation Secuencia de oligonucleótidos inmunoestimuladores y métodos para usar los mismos
JP2005055812A (ja) 2003-08-07 2005-03-03 Olympus Corp プロジェクタ装置及びそれを組み込んだ机
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
EP1756138A4 (en) 2004-03-05 2009-07-01 Archemix Corp APTAMERS FACILITATED TO THE FAMILY OF HUMAN IL-12 CYTOKINS AND THEIR USE AS THERAPEUTICS AGAINST AUTOIMMUNE DISEASES
US20060193821A1 (en) 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
AU2005282889B2 (en) 2004-09-01 2012-03-15 Dynavax Technologies Corporation Methods and conpositions for inhibition of innate immune responses and autoimmunity
CA2591582A1 (en) 2004-12-17 2006-06-22 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
US7608395B2 (en) 2005-09-15 2009-10-27 Baylor Research Institute Systemic lupus erythematosus diagnostic assay
EP2341059A1 (en) 2005-10-12 2011-07-06 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
WO2007075626A2 (en) 2005-12-20 2007-07-05 Idera Pharmaceuticals, Inc. Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo tm) contiaining different lengths of palindromic segments
EP1986697B1 (en) 2006-02-17 2016-06-29 GE Healthcare Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
KR101221589B1 (ko) 2006-04-07 2013-01-15 이데라 파마슈티칼즈, 인코포레이티드 Ｔｌｒ７ 및 ｔｌｒ８에 대한 안정화된 면역 조절성 ｒｎａ〔ｓｉｍｒａ〕 화합물
AU2007260775A1 (en) 2006-06-13 2007-12-21 Bayhill Therapeutics, Inc. Methods and immune modulatory nucleic acid compositions for preventing and treating disease
WO2008008531A2 (en) 2006-07-13 2008-01-17 John Edward O'neill Configurable board game
EP1881080A1 (en) 2006-07-18 2008-01-23 Institut Gustave Roussy Toll like receptor 4 dysfunction and the biological applications thereof
CA2703931C (en) 2007-10-26 2016-08-16 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
WO2009058361A1 (en) 2007-10-31 2009-05-07 Dynavax Technologies Corp. Inhibition of type i ifn production
PL2154144T3 (pl) 2008-08-06 2015-04-30 Changchun Huapu Biotechnology Co Ltd Oligonukleotydy i ich zastosowanie
US8940310B2 (en) * 2010-06-16 2015-01-27 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
JP5921535B2 (ja) 2010-06-16 2016-05-24 ディナバックス テクノロジーズ コーポレイション Ｔｌｒ７および／またはｔｌｒ９阻害剤を用いる治療の方法

Also Published As

Publication number Publication date
HK1183809A1 (zh) 2014-01-10
AU2011268211A1 (en) 2013-01-10
CA2802873C (en) 2018-09-18
WO2011159958A2 (en) 2011-12-22
EP2582398A2 (en) 2013-04-24
KR20130043155A (ko) 2013-04-29
US20130156814A1 (en) 2013-06-20
MX2012014904A (es) 2013-08-08
US20150203850A1 (en) 2015-07-23
BR112012032240A2 (pt) 2019-09-24
KR101810593B1 (ko) 2017-12-22
WO2011159958A9 (en) 2013-06-06
SG186380A1 (en) 2013-01-30
CN103153346A (zh) 2013-06-12
CA2802873A1 (en) 2011-12-22
EP2582398A4 (en) 2014-04-30
EP2582398B1 (en) 2016-04-13
AU2011268211B2 (en) 2015-07-16
US8940310B2 (en) 2015-01-27
US9347064B2 (en) 2016-05-24
EA201291357A1 (ru) 2013-11-29

Similar Documents

Publication Publication Date Title
MX338980B (es) Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9.
UA116092C2 (uk) Спосіб та композиція для боротьби з бур'янами (варіанти)
IN2012DN03883A (es)
IN2015DN00127A (es)
CA2871471C (en) Dna-pk inhibitors
GB2502650B (en) Adaptive and targeted control of ion populations to improve the effective dynamic range of mass analyser
EA201201648A1 (ru) Стимуляторы sgc
PH12014502445A1 (en) Targeted modification of malate dehydrogenase
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
UA116091C2 (uk) Способи та композиції для боротьби з бур'янами
MX2013012165A (es) Composicion y metodo para mejorar una respuesta inmune.
MX350773B (es) Métodos y composiciones para el control de malezas.
MX343072B (es) Metodos y composiciones para controlar malezas.
JO3306B1 (ar) تراكيب وطرق لطلاء الأظافر قابل للمعالجة بالأشعة فوق البنفسجية
WO2012142498A3 (en) Mif inhibitors and their uses
MX2013005549A (es) Aminas heterociclicas y sus usos.
HK1216175A1 (zh) 治療性化合物和組合物
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX2014013752A (es) Inhibidores de nampt.
MX354988B (es) Formulaciones de anticuerpo y metodos.
PH12014502513A1 (en) Nampt inhibitors
HK1213471A1 (zh) 作為蛋白脫乙酰基酶抑制劑的嘧啶羥基酰胺化合物及其使用方法
WO2013003298A3 (en) Inhibitors of pde10
MX348311B (es) Inhibidores nampt.
WO2013057013A3 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration